ReachMD

Dr. David Borsook is a neurologist and neurobiologist by training. He holds appointments at McLean Hospital, Massachusetts General Hospital (MGH), Children's Hospital Boston and Harvard Medical School. He was the director of the MGH Pain Program and Cancer Pain Program for five years and involved in a number of national and international pain programs, including the World Health Organization Cancer Pain Initiative in China. In 1994 while at MGH, Dr. Borsook established a research program investigating the use of fMRI in pain and analgesia with the support of the National Institutes of Health (NIH) and other nonprofit research foundations. 

With respect to biomarker development he has had experience in the private sector, as a co-founder Descartes Therapeutics, Inc., a venture-backed biotech that aimed to use fMRI in drug development where he was the chief scientific officer and executive vice president. In 2004, Dr. Borsook returned to academia where he has led two programs - the PAIN Group and the Imaging Center for Drug Development - an academic/industry program to evaluate the utility of imaging in drug development. He has written extensively, with over 100 scientific publications, including editing three books, one on the use of Imaging in CNS Drug Development that has been a representative on a number of NIH-related think tanks in the field of pain. Dr. Borsook has recently led an effort to establish research in biomarker development through the Biomarker Consortium.